Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in IrelandArchived
Rotavirus gastroenteritis in Ireland is a quite common and unpleasant illness, but severe disease is unusual and death extremely rare. Nonetheless, rotavirus generates considerable direct and indirect costs.
Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M. Vaccine. 2011 Oct 6;29(43):7463-73.
Although vaccines currently available are safe and efficacious, the option of universal vaccination coverage is too costly in Ireland under the base case assumptions. However, future vaccine price reductions, e.g. following competitive tendering, might lead to reconsider the issue.
Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Pre-Term European Infants: A Randomized Phase IIIb StudyArchived
1 Feb 2012 - Results of this study demonstrated that the RIX4414 vaccine was well tolerated and immunogenic in pre-term European infants: more than 75% of infants had seroconverted 30-83 days after dose 2.
Impact of rotavirus vaccination on epidemiological dynamics in England and WalesArchived
9 Dec 2011 - The paper shows, through mathematical modelling, the impact of mass rotavirus vaccination in England and Wales.
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialArchived
14 Sep 2011 - These article published in The Lancet provide new data for the efficacy of oral pentavalent rotavirus vaccine for prevention of severe rotavirus – related gastroenteritis in infant in developing countries